Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)

Trial Profile

Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs ACP 001 (Primary) ; Growth hormones
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms TransCon PEG hGH
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2016 Results assessing optimal release profile of unmodified hGH from the prodrug and to predict the relationship between TransCon Growth Hormone dose and serum concentrations of released unmodified hGH presented at The 98th Annual Meeting of the Endocrine Society.
    • 08 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top